Skip to content

Phone calls follow-up in the care of cancer patients under ambulatorial anti-cancer therapy: randomized clinical test

Telenursing in the care of cancer patients under ambulatorial antineoplastic therapy: randomized clinical test

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-9g7kvc
Enrollment
Unknown
Registered
2019-06-14
Start date
2018-02-15
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nausea

Interventions

First stage - 1st measurement: evaluation using the QLQ-C30 instrument to establish a baseline quality of life and symptoms presented by the clients + face-to-face intervention about the side effects
Other

Sponsors

Universidade Federal do Ceará
Lead Sponsor
Ambulatório de Quimioterapia do Hospital Universitário Walter Cantídio
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients with diagnose of solid cancers of gastrointestinal tract, breast and lungs, because these represent the majority of people assisted in the referred outpatient care; Patients who are in the first or second chemotherapy cycle; Patients whose age is superior to 18 years old; Patients who scored 15 in Glasgow Coma Scale.

Exclusion criteria

Exclusion criteria: Patients who reached scores inferior to 60%.

Design outcomes

Primary

MeasureTime frame
Comparing to the control group, participants in the experimental group who will receive telenursing to manage the side effects of chemotherapy will report better quality of life and lower scores of symptoms.

Secondary

MeasureTime frame
Comparing to the control group, participants in the experimental group who will receive telenursing to manage the side effects of chemotherapy will report better quality of life and lower scores of symptoms, such as nausea, vomiting, inappetence, constipation, diarrhea, peripheral neuropathy , anxiety, sleep problems and myelosuppression (risk of infection and risk of bleeding).

Countries

Brazil

Contacts

Public ContactAndrea Rodrigues

Universidade Federal do Ceará

andreabrodrigues@gmail.com558533668454

Outcome results

None listed

Source: REBEC (via WHO ICTRP)